FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and to pharmacy. Disclosed is the use of an inhibitor of aldosterone synthase CYP11B2, a compound of formula I or a salt thereof, solvate, hydrate (version: use of a pharmaceutical composition containing an effective amount of at least one said compound) for treating and/or preventing a disease/pathological condition caused by aldosterone hyper-synthesis.
EFFECT: technical result: compounds of formula I inhibit activity of CYP11B2 in the absence or weak binding with steroid enzymes involved in the metabolism of drug compounds, not inhibiting steroidogenic enzymes of family P450 and are not cytotoxic, use thereof enables reducing the level of aldosterone and eliminating disorders caused by its excess, without side effects caused by inhibition of synthesis of glucocorticoid hormones.
8 cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2800378C1 |
HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2022 |
|
RU2811745C1 |
HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2023 |
|
RU2824362C1 |
HUMAN CYTOCHROME 11B2 INHIBITORS | 2021 |
|
RU2783521C1 |
HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2789610C1 |
HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION AND USE THEREOF | 2020 |
|
RU2823875C1 |
BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR TREATING CANCER | 2015 |
|
RU2741914C2 |
PYRROLO-PYRROLE COMPOSITIONS AS ACTIVATORS OF PYRUVATE KINASE (PKR) | 2018 |
|
RU2736217C2 |
FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | 2007 |
|
RU2427577C2 |
FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | 2007 |
|
RU2436778C2 |
Authors
Dates
2020-03-20—Published
2019-06-04—Filed